EXPLORING SEX-DIVERSITY OF GENE MUTATIONS AND RESPONSE TO ESA TREATMENT IN LOW-RISK MYELODYSPLASTIC NEOPLASMS

EHA Library, Marco Raddi, 420830

IMPACT OF COMPLETE CYTOGENETIC RESPONSE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, Samuel Urrutia, 420831

REAL-WORLD DOSE ESCALATION AND OUTCOMES AMONG PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING LUSPATERCEPT IN CLINICAL PRACTICE

EHA Library, Kashyap Patel, 420832

THE HUMANISTIC AND ECONOMIC BURDEN OF TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES ON PATIENTS IN NORTH AMERICA AND EUROPE

EHA Library, María Díez Campelo, 420833

ORAL DECITABINE/CEDAZURIDINE WITH VENETOCLAX VERSUS ORAL DECITABINE/CEDAZURIDINE IN HIGH-RISK MYELODYSPLASTIC SYNDROME: A PROPENSITY SCORE MATCHED ANALYSIS

EHA Library, Alex Bataller, 420834

ASSESSMENT OF CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WHO WERE TREATED WITH ORAL DECITABINE/CEDAZURIDINE (DEC-C) USING THE INTERNATIONAL WORKING GROUP (IWG) 2023 CRITERIA

EHA Library, Amer M. Zeidan, 420835

CLINICAL IMPLICATIONS OF SPLICING FACTOR MUTATIONS IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROMES/NEOPLASMS TREATED WITH HYPOMETHYLATING AGENTS (HMA)- A MULTICENTER, RETROSPECTIVE ANALYSIS

EHA Library, Tariq Kewan, 420836

PHASE 1B STUDY OF SL-172154, A BI-FUNCTIONAL FUSION PROTEIN TARGETING CD47 AND CD40, WITH AZACITIDINE IN PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA AND HIGHER-RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Amer Zeidan, 420837

RELATIONSHIP BETWEEN HAEMOGLOBIN AND QUALITY OF LIFE IN TRANSFUSION-DEPENDENT PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROME RECEIVING LUSPATERCEPT OR EPOETIN ALFA

EHA Library, Esther N. Oliva, 420838

CLINICAL IMPLICATIONS OF IDH MUTATIONS (IDH MT) IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/NEOPLASMS (MDS) TREATED WITH HYPOMETHYLATING AGENTS (HMA)

EHA Library, Tariq Kewan, 420839

CPH DEEP NEURAL NETWORK DEMONSTRATES THAT IWG-2023-PROPOSED LOWERING OF HB THRESHOLD TO ≥10G/DL FOR RESPONSE ASSESSMENT DOES NOT RESULT IN WORSE OUTCOME PREDICTION THAN ≥11G/DL AS ASSESSED BY PB-CR

EHA Library, Lisa Pleyer, 420840

PREVALENCE AND CLINICAL SIGNIFICANCE OF GERMLINE VARIANTS IN CEBPA, DDX41, ETV6, GATA2 AND RUNX1 AMONG PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, Anna Tranberg, 420841

REAL-LIFE ANEMIA TREATMENT   IN LOW-RISK MYELODYSPLATIC SYNDROME (MDS) PATIENTS: A RETROSPECTIVE MULTICENTER STUDY BY THE GROUPE FRANCOPHONE DES MYÉLODYSPLASIES (GFM) ON 194 PATIENTS

EHA Library, abdessamia gandoul, 420842

MULTILINEAGE AND SAFETY RESULTS FROM THE COMMANDS TRIAL IN TRANSFUSION-DEPENDENT, ERYTHROPOIESIS-STIMULATING AGENT-NAIVE PATIENTS WITH VERY LOW-, LOW-, OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Guillermo Garcia-Manero, 420844

PERIPHERAL BLOOD COMPLETE REMISSION (PB-CR) IS ASSOCIATED WITH SIMILAR SURVIVAL AS CR PER IWG 2023 CRITERIA IN PATIENTS WITH HIGHER-RISK MDS – AN INTERNATIONAL STUDY FROM THE VALIDATE CONSORTIUM

EHA Library, Tariq Kewan, 420845

QUANTIFYING THE RELATIONSHIP BETWEEN TRANSFUSION INDEPENDENCE AND OVERALL SURVIVAL IN LOWER-RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Luca Malcovati, 420846

SPECTRUM AND CLINICAL IMPLICATIONS OF EXTRAMEDULLARY MANIFESTATIONS IN CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Guillermo Montalban-Bravo, 420847

CHARACTERISATION AND PROGNOSTIC IMPACT OF ZRSR2 MUTATIONS IN MYELOID NEOPLASMS

EHA Library, Aref Al-Kali, 420848

CLINICAL BENEFIT OF LUSPATERCEPT IN TRANSFUSION-DEPENDENT, ERYTHROPOIESIS-STIMULATING AGENT-NAIVE PATIENTS WITH VERY LOW-, LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES IN THE COMMANDS TRIAL

EHA Library, Valeria Santini, 420849

VALIDATION OF IWG-2023 RESPONSE CRITERIA, EXPANSION TO INCLUDE ALL MDS/CMML/AML PATIENTS TREATED WITH AZACITIDINE, AND COMPARISON WITH IWG-2006 AND ELN-2022 CRITERIA USING A CPH DEEP NEURAL NETWORK

EHA Library, Lisa Pleyer, 420850

PROGNOSTIC FACTORS IN UNTREATED PATIENTS WITH MYELODYSPLASTIC SYNDROMES WITH ISOLATED 5Q DELETION

EHA Library, Maria Julia Montoro, 420851

PHASE I/II STUDY OF SECLIDEMSTAT, AN LSD1 INHIBITOR, IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Guillermo Montalban-Bravo, 420852

VALUE OF EARLY LUSPATERCEPT USE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS)

EHA Library, David Valcárcel, 420853

RED BLOOD CELL TRANSFUSION DEPENDENCY BURDEN IN LOWER-RISK MYELODYSPLASTIC SYNDROME PATIENTS IN FRANCE - EDELWEISS STUDY

EHA Library, Thibault Comont, 420854

CLINICAL SIGNIFICANCE OF GENOMIC LANDSCAPE IN PEDIATRIC ADVANCED MDS

EHA Library, chenmeng Liu, 420855

TARGETING LILRB4 (ILT3) USING IO-202 IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): INTERIM EFFICACY, SAFETY, AND MECHANISM OF ACTION DATA FROM THE PHASE 1B EXPANSION COHORT

EHA Library, Ahmed Aribi, 420856

RECLASSIFICATION MDS PATIENTS AND FURTHER EVALUATION THE IMPACT OF BONE MARROW FIBROSIS ACCORDING TO 5TH (2022) EDITIONS OF THE WHO CLASSIFICATION OF MYELODYSPLASTIC NEOPLASMS

EHA Library, Gaixiang Xu, 420857

RISK STRATIFICATION IN HYPOMETHYLATING AGENT-TREATED PATIENTS WITH MYELODYSPLASTIC SYNDROMES: A MULTIVARIATE MODEL

EHA Library, Kelly Chien, 420858

THE DYNAMIC CHANGES OF GENETIC MUTATIONS DURING THE DISEASE COURSE OF MYELODYSPLASTIC NEOPLASMS

EHA Library, Zheng Ge, 420859

VALIDATION AND COMPARISON OF 5TH EDITION WHO CLASSIFICATION (WHO 2022) AND INTERNATIONAL CONSENSUS CLASSIFICATION (ICC) PROPOSALS FOR MDS-SFB31

EHA Library, Linlin Liu, 420860

MYELODYSPLASTIC SYNDROMES WITH CONCOMITANT SF3B1 MUTATION AND DELETION OF THE LONG ARM OF CHROMOSOME 5

EHA Library, Zaker Schwabkey, 420861

ES-3000, A WNT/ Β CATENIN/INFLAMMASOME PATHWAY INHIBITOR COMBINED WITH ORAL DECITABINE/CEDAZURIDINE(ASTX727) FOR PATIENTS WITH MYELODYSPLASIA

EHA Library, Anoop Enjeti, 420862

QUESTIONABLE BENEFIT OF PRIOR THERAPY IN MDS PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS OF THE EBMT CHRONIC MALIGNANCIES WORKING PARTY

EHA Library, Christoph Scheid, 420863

A PHASE I STUDY OF ANTI-TIM-3 ANTIBODY TQB2618 ADDED TO HYPOMETHYLATING AGENTS (HMAS) IN ADULT PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)

EHA Library, Yu Wu, 420864

AN IMMUNE DYSFUNCTION SIGNATURE ROBUSTLY ILLUMINATES DISEASE DYNAMICS AND PREDICTS SURVIVAL IN MDS/CMML PATIENTS: INSIGHTS FROM A LONGITUDINAL, MULTICENTER STUDY

EHA Library, Yu-Hung Wang, 420865

THE IMPLICATION OF TP53 ALLELIC STATUS FOR OUTCOME AND ERYTHROPOIESIS IN MDS

EHA Library, Bing Li, 420866

MOLECULAR EVENTS CONTRIBUTING TO THE IMMUNE-MEDIATED BONE MARROW FAILURE IN IDIOPATHIC APLASTIC ANEMIA

EHA Library, Zuzana Lenertova, 420867

SPLICING ALTERATIONS CAUSED BY U2AF1MT-S34 MODIFY THE TRANSCRIPTOME OF POT1 IN PATIENTS WITH TELOMERE BIOLOGY DISORDERS

EHA Library, Alejandro Ferrer, 420868

ZMAT3 PREVENTS HEMATOPOIETIC STEM CELL EXHAUSTION AND CONTRIBUTES TO CELL TRANSFORMATION BY MODULATING SPHINGOLIPID METABOLISM IN FANCONI ANEMIA DISEASE.

EHA Library, Maeva Loock, 420869

METABOLOMICS AND OXIDATIVE DAMAGE IN DIAMOND-BLACKFAN ANEMIA

EHA Library, Ondrej Jahoda, 420870

LONG-READ HLA SEQUENCING UNCOVERS SPECIFIC RISK ALLELES AND CLINICAL ASSOCIATIONS IN APLASTIC ANEMIA

EHA Library, Sunisa Kongkiatkamon, 420871

SPECTRUM OF GENETIC VARIANTS IN AN ARGENTINE PEDIATRIC COHORT WITH SUSPECTED INHERITED BONE MARROW FAILURE SYNDROMES

EHA Library, Agustina Albero, 420872

MUC4 GENE MUTATION PROMOTE COMPLEMENT DEPOSITION AND INCREASE THE RISK OF THROMBOTIC EVENTS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Rong Fu, 420873

EXPRESSION AND MECHANISM OF ACTION OF ASH1L IN NK CELL OF SEVERE APLASTIC ANAEMIA

EHA Library, Mengran Gao, 420874

GENETIC VARIANTS AND INBORN ERRORS OF IMMUNITY IN BONE MARROW FAILURE: NOVEL POTENTIAL DRUG TARGETS FOR PRECISION MEDICINE

EHA Library, Vanessa Desantis, 420875

EFFICACY AND SAFETY OF INTENSIVE PEGCETACOPLAN DOSING FOR THE TREATMENT OF ACUTE HEMOLYSIS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Morag Griffin, 420876

A NOVEL AUTOSOMAL RECESSIVE TELOMERE BIOLOGY DISORDER CAUSED BY BIALLELIC VARIANTS IN POLA2

EHA Library, Bianca Tesi, 420877

LATE ONSET AND LONG LASTING NEUTROPENIA  IN CHILDREN AND CHRONIC IDIOPATHIC NEUTROPENIA IN ADULTS: DESCRIPTION OF CLINICAL/ IMMUNOLOGICAL PHENOTYPE AND PRELIMINARY WES RESULTS.

EHA Library, Francesca Fioredda, 420878

CLINICAL CHARACTERISTICS AND PROGNOSIS OF SHWACHMAN-DIAMOND SYNDROME PATIENTS WITH MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA  IN CHINA

EHA Library, Yang Wan, 420879

LONG-TERM OUTCOMES OF PEGCETACOPLAN TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND BASELINE HEMOGLOBIN LEVELS GREATER THAN 10 GRAMS PER DECILITER

EHA Library, Jens Panse, 420880

OUTPATIENT SUBCUTANEOUS ALEMTUZUMAB IS FEASIBLE AND SAFE FOR APLASTIC ANEMIA AND ASSOCIATED WITH HIGH RESPONSE RATES.

EHA Library, Celso Arrais-Rodrigues, 420881

MUTATIONAL LANDSCAPE IN PATIENTS WITH SEVERE APLASTIC ANEMIA IN TAIWAN AND THE CLINICAL SIGNIFICANCE

EHA Library, Kuojui Sun, 420882

CHARACTERIZATION OF CLINICALLY SIGNIFICANT BREAKTHROUGH HEMOLYSIS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH PEGCETACOPLAN

EHA Library, Régis Peffault de Latour, 420883

LONGITUDINAL ASSESSMENT OF CLONAL HEMATOPOIESIS DYNAMICS IN CHRONIC IDIOPATHIC NEUTROPENIA (CIN)

EHA Library, Grigorios Tsaknakis, 420884

CLINICAL HETEROGENEITY AND OUTCOME OF PURE RED CELL APLASIA (PRCA): A MULTICENTER INTERNATIONAL STUDY

EHA Library, Francesco Versino, 420885

EFFECTS OF ORAL IPTACOPAN MONOTHERAPY, INCLUDING INCREASED PAROXYSMAL NOCTURNAL HEMOGLOBINURIA RED BLOOD CELL CLONE SIZE, ARE MAINTAINED IN COMPLEMENT INHIBITOR-NAÏVE PATIENTS: FINAL APPOINT-PNH DATA

EHA Library, Antonio Risitano, 420886

PURE RED CELL APLASIA ASSOCIATED WITH THYMIC TUMOURS: A NATIONWIDE COHORT

EHA Library, Mylène Hemmer, 420887

EPIDEMIOLOGY AND REAL-WORLD TREATMENT MANAGEMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN FRANCE

EHA Library, Régis Peffault de Latour, 420888

BREAKTHROUGH HEMOLYSIS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH COMPLEMENT INHIBITORS: A MULTICENTER INTERNATIONAL STUDY

EHA Library, Bruno Fattizzo, 420890

PREDICTIVE FACTORS FOR THE RESPONSE TO ROMIPLOSTIM IN PATIENTS WITH IST-REFRACTORY APLASTIC ANEMIA: DATA FROM TWO CLINICAL TRIALS

EHA Library, Jun-Ho Jang, 420891

RESULTS FROM THE OPEN-LABEL EXTENSION PERIOD OF A PHASE 2 TRIAL EVALUATING THE SAFETY AND EFFICACY OF POZELIMAB AND CEMDISIRAN COMBINATION IN PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA

EHA Library, Rodrigo Pavani, 420892

EFFECTS OF ORAL IPTACOPAN MONOTHERAPY, INCLUDING INCREASED PAROXYSMAL NOCTURNAL HEMOGLOBINURIA RED BLOOD CELL CLONE SIZE, ARE SUSTAINED IN ANTI-C5-TREATED PATIENTS WITH ANEMIA: FINAL APPLY-PNH DATA

EHA Library, Régis Peffault de Latour, 420893

TREATMENT PATTERNS AND OUTCOMES OF PATIENTS (PTS) WITH ACQUIRED APLASTIC ANEMIA (AA) IN THE UNITED STATES (US): RESULTS FROM A LARGE AND UNIQUE NATIONAL CLAIMS DATABASE

EHA Library, Jessica M. Stempel, 420894

INFLUENTIAL CLINICAL FACTORS ON TELOMERE LENGTH IN PEDIATRIC APLASTIC ANEMIA

EHA Library, Zixi Yin, 420895

ACCESS TO EXPENSIVE DRUGS IN EU COUNTRIES FOR VERY RARE HEMATOLOGICAL BLOOD DISORDERS: THE EXAMPLE OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA. A SURVEY BY ERN-EUROBLOODNET

EHA Library, Mariangela Pellegrini, 420896

REAL-WORLD CLINICAL OUTCOMES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH ECULIZUMAB OR RAVULIZUMAB IN THE US - A RETROSPECTIVE CLAIMS DATABASE ANALYSIS

EHA Library, Srinivas Tantravahi, 420897

CLINICAL PHARMACOLOGY OF OMS906, A POTENT INHIBITOR OF MASP-3 AND THE ALTERNATIVE PATHWAY OF COMPLEMENT ACTIVATION

EHA Library, William Pullman, 420898

EFFICACY AND SAFETY OF POZELIMAB PLUS CEMDISIRAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA WHO ARE NAÏVE TO COMPLEMENT INHIBITION

EHA Library, Morag Griffin, 420899

CLINICAL FEATURES AND OUTCOMES IN LARGE GRANULAR LYMPHOCYTE LEUKEMIAÂ ASSOCIATED PURE RED CELL APLASIA WITH STAT3 MUTATION

EHA Library, Guangsheng He, 420900

PHARMACOKINETIC CHARACTERIZATION AND EXPOSURE-RESPONSE RELATIONSHIP OF CROVALIMAB IN THE COMMODORE 1, 2, AND 3 AND COMPOSER TRIALS OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

EHA Library, Rong Fu, 420901

THROMBOSIS AND MENINGOCOCCAL INFECTION RATES IN PEGCETACOPLAN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN THE POST-MARKETING SETTING

EHA Library, Jens Panse, 420902

PHASE III COMMODORE 1 AND COMMODORE 2 TRIALS: TREATMENT SATISFACTION AND PREFERENCE IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATED WITH CROVALIMAB AND ECULIZUMAB OR RAVULIZUMAB

EHA Library, Austin Kulasekararaj, 420903

ELTROMBOPAG PROMOTES THE ENGRAFTMENT OF BONE MARROW FAILURE SYNDROME WITH ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Meng Zhou, 420904

IMPROVEMENT IN IRON OVERLOAD WITH PEGCETACOPLAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PREVIOUSLY TREATED WITH ECULIZUMAB

EHA Library, David Kuter, 420905

ADVANCING INSIGHTS INTO MONOCLONAL ANTIBODY MECHANISMS: A NOVEL EX VIVO ASSAY USING WHOLE BONE MARROW ENVIRONMENT TO INVESTIGATE THE EFFICACY OF DARATUMUMAB IN MULTIPLE MYELOMA.

EHA Library, Jenifer Sanchez, 420906

NONO IS REQUIRED FOR MULTIPLE MYELOMA CELL LINES GROWTH THROUGH STABILISATION OF LNCRNA NEAT1 AND PARASPECKLE INTEGRITY

EHA Library, Elisa Taiana, 420907

BLOCKING LACTATE METABOLISM TO ENHANCE CAR-T THERAPY EFFECT ON MULTIPLE MYELOMA PATIENTS

EHA Library, Zhaoyun Liu, 420908

IRF2 REGULATES SPECIFIC SIGNALING PATHWAYS THAT PARTICIPATE IN THE DEVELOPMENT AND PATHOGENESIS OF MULTIPLE MYELOMA

EHA Library, Nahia Gomez-Echarte, 420909

INFLAMMATORY BONE MARROW MICROENVIRONMENT IMPAIRS RESPONSES TO DARATUMUMAB AND LENALIDOMIDE IN MULTIPLE MYELOMA. A CORRELATIVE STUDY OF THE IFM2017-03 TRIAL.

EHA Library, Silvia Gaggero, 420910

IBERDOMIDE IS IMMUNE STIMULATORY AND INDUCES DEEP ANTI-MYELOMA ACTIVITY ACROSS DOSES IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH TNE NDMM FROM THE CC-220-MM-001 STUDY

EHA Library, Michael Amatangelo, 420911

NON-CODING RNAS REGULATE NOVEL SIGNALING PATHWAYS IN AL AMYLOIDOSIS THAT ARE TARGETABLE BY FDA APPROVED DRUGS

EHA Library, Tal Zvida-Bloch, 420912

FUNCTIONAL DISSECTION AND CLINICAL RELEVANCE  OF THE SINGLE CELL TRANSCRIPTOMIC LANDSCAPE OF GENOTYPICALLY-IDENTIFIED POLYCLONAL PLASMACELLS IN MULTIPLE MYELOMA MICROENVIRONMENT

EHA Library, matteo claudio da via', 420913

EXPRESSION PATTERN OF P53 POST-TRANSLATIONAL MODIFICATIONS AND ITS CLINICAL IMPACT IN HOMOGENOUSLY TREATED MULTIPLE MYELOMA PATIENTS.

EHA Library, Elizabeta A. Rojas, 420914

ALTERATIONS IN CHROMATIN ACCESSIBILITY OF PLASMA CELLS ALLOW NUCLEAR RESPIRATORY FACTOR 1 (NRF1) TO PROMOTE THE DEVELOPMENT AND PROGRESSION OF MULTIPLE MYELOMA.

EHA Library, Giacomo Corleone, 420915

CD4+ CYTOTOXIC T LYMPHOCYTES CONTRIBUTE TO ANTITUMOR IMMUNITY IN MULTIPLE MYELOMA

EHA Library, Hyunsoo Cho, 420916

IMPACT OF PRIOR ANTIBIOTIC EXPOSURE BEFORE INITIATING BISPECIFIC MONOCLONAL ANTIBODY THERAPY IN MULTIPLE MYELOMA

EHA Library, Roberto Garcia-Vicente, 420917

IMPLICATION OF GLYCOLYTIC AND MITOCHONDRIAL METABOLISM IN MULTIPLE MYELOMA RESPONSE TO ANTI-CD38 DARATUMUMAB TREATMENT

EHA Library, Alizée Steer, 420918

DECIPHERING MULTIPLE MYELOMA COMPLEXITY: EXPLORING TUMOR MICROENVIRONMENT DYNAMICS THROUGH MULTI-OMICS INTEGRATION FOR PERSONALIZED THERAPEUTIC INSIGHTS

EHA Library, Elina Alaterre, 420919

HIGH-RESOLUTION SINGLE-CELL RNA SEQUENCING (SCRNA-SEQ) DEFINES DISTINCT NEUTROPHIL GENE SIGNATURES WITHIN FOCAL LESIONS LINKED TO MULTIPLE MYELOMA PROGRESSION FREE SIGNATURE

EHA Library, Philip Mccarthy, 420920

EXPLOITING APOBEC3B-INDUCED VULNERABILITIES FOR RISK-ADAPTED TREATMENT IN MM PATIENTS WITH DEL(17P)

EHA Library, Afsaneh Panahi, 420921

GENETIC DISRUPTION OF BLIMP-1 REMODELS THE TRANSCRIPTOME OF ARI0002H, AN ACADEMIC BCMA-TARGETING CAR-T CELL, TOWARDS A MORE FAVORABLE DIFFERENTIATION PROFILE AND IMPROVED ANTI-TUMOR EFFICACY

EHA Library, Anthony Battram, 420922

CHARACTERIZATION OF BONE MARROW NICHE AND IMMUNOPHENOTYPING IN A MULTIPLE MYELOMA MOUSE MODEL DRIVEN BY COMBINED EXPRESSION OF ACTIVE RANK AND TCL1

EHA Library, Lisa Pfeuffer, 420923

MULTI-OMIC ANALYSIS OF MULTIPLE MYELOMA BY T(11;14) STATUS

EHA Library, Andrew Spencer, 420924

VALIDATION OF PROTOTYPE BIOMARKERS TO IDENTIFY RISK FACTORS OF INFLAMMATORY ADVERSE EVENTS FOLLOWING IDECABTAGENE VICLEUCEL INFUSION IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN KARMMA-3

EHA Library, Salomon Manier, 420925

INCREASED WEE1 EXPRESSION CORRELATES WITH POOR SURVIVAL IN MULTIPLE MYELOMA INDEPENDENT OF STANDARD PROGNOSTIC FACTORS

EHA Library, Anish Simhal, 420926

CLINICAL BIOMARKERS ASSOCIATED WITH PROGRESSION FREE SURVIVAL TO CILTACABTAGENE AUTOLEUCEL IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM CARTIFAN-1 STUDY

EHA Library, Jian‑Qing Mi, 420927

UNRAVELLING THE ROLE OF THE NON-IMMUNE BONE MARROW MICROENVIRONMENT IN THE PROGRESSION FROM MGUS TO SMOULDERING AND MULTIPLE MYELOMA

EHA Library, Miguel Cócera Fernández, 420928

GENETIC CHARACTERIZATION OF T(11;14) POSITIVE NEWLY DIAGNOSED MULTIPLE MYELOMA AND MANTLE CELL LYMPHOMA PATIENTS

EHA Library, Jana Wobst, 420929

ALTERATIONS IN EXPRESSION OF GENES CONTROLLING CELL SURFACE SIALYLATION IMPACT PROGNOSIS OF PATIENTS TREATED WITH CURRENT ANTI-MYELOMA THERAPIES

EHA Library, Michael O'Dwyer, 420930

CYCLOPHOSPHAMIDE-POMALIDOMIDE COMBINATION ALTERS THE TUMOUR CELL SECRETOME AND ENHANCES THE ANTI-MYELOMA ACTIVITY OF ELOTUZUMAB THROUGH NK MEDIATED CYTOTOXICITY

EHA Library, Michael O'Dwyer, 420931